Functional selectivity and time‐dependence of μ‐opioid receptor desensitization at nerve terminals in the mouse ventral tegmental area
Background and Purpose The majority of studies examining desensitization of the μ‐opioid receptor (MOR) have examined those located at cell bodies. However, MORs are extensively expressed at nerve terminals throughout the mammalian nervous system. This study is designed to investigate agonist‐induce...
Saved in:
Published in | British journal of pharmacology Vol. 172; no. 2; pp. 469 - 481 |
---|---|
Main Authors | , |
Format | Journal Article |
Language | English |
Published |
England
Blackwell Publishing Ltd
01.01.2015
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Background and Purpose
The majority of studies examining desensitization of the μ‐opioid receptor (MOR) have examined those located at cell bodies. However, MORs are extensively expressed at nerve terminals throughout the mammalian nervous system. This study is designed to investigate agonist‐induced MOR desensitization at nerve terminals in the mouse ventral tegmental area (VTA).
Experimental Approach
MOR function was measured in mature mouse brain slices containing the VTA using whole‐cell patch‐clamp electrophysiology. Presynaptic MOR function was isolated from postsynaptic function and the functional selectivity, time‐dependence and mechanisms of agonist‐induced MOR desensitization were examined.
Key Results
MORs located at GABAergic nerve terminals in the VTA were completely resistant to rapid desensitization induced by the high‐efficacy agonists DAMGO and Met‐enkephalin. MORs located postsynaptically on GABAergic cell bodies readily underwent rapid desensitization in response to DAMGO. However, after prolonged (>7 h) treatment with Met‐enkephalin, profound homologous MOR desensitization was observed. Morphine could induce rapid MOR desensitization at nerve terminals when PKC was activated.
Conclusions and Implications
Agonist‐induced MOR desensitization in GABAergic neurons in the VTA is compartment‐selective as well as agonist‐selective. When MORs are located at cell bodies, higher‐efficacy agonists induce greater levels of rapid desensitization than lower‐efficacy agonists. However, the converse is true at nerve terminals where agonists that induce MOR desensitization via PKC are capable of rapid agonist‐induced desensitization while higher‐efficacy agonists are not. MOR desensitization induced by higher‐efficacy agonists at nerve terminals only takes place after prolonged receptor activation.
Linked Articles
This article is part of a themed section on Opioids: New Pathways to Functional Selectivity. To view the other articles in this section visit http://dx.doi.org/10.1111/bph.2015.172.issue-2 |
---|---|
AbstractList | The majority of studies examining desensitization of the μ-opioid receptor (MOR) have examined those located at cell bodies. However, MORs are extensively expressed at nerve terminals throughout the mammalian nervous system. This study is designed to investigate agonist-induced MOR desensitization at nerve terminals in the mouse ventral tegmental area (VTA).
MOR function was measured in mature mouse brain slices containing the VTA using whole-cell patch-clamp electrophysiology. Presynaptic MOR function was isolated from postsynaptic function and the functional selectivity, time-dependence and mechanisms of agonist-induced MOR desensitization were examined.
MORs located at GABAergic nerve terminals in the VTA were completely resistant to rapid desensitization induced by the high-efficacy agonists DAMGO and Met-enkephalin. MORs located postsynaptically on GABAergic cell bodies readily underwent rapid desensitization in response to DAMGO. However, after prolonged (>7 h) treatment with Met-enkephalin, profound homologous MOR desensitization was observed. Morphine could induce rapid MOR desensitization at nerve terminals when PKC was activated.
Agonist-induced MOR desensitization in GABAergic neurons in the VTA is compartment-selective as well as agonist-selective. When MORs are located at cell bodies, higher-efficacy agonists induce greater levels of rapid desensitization than lower-efficacy agonists. However, the converse is true at nerve terminals where agonists that induce MOR desensitization via PKC are capable of rapid agonist-induced desensitization while higher-efficacy agonists are not. MOR desensitization induced by higher-efficacy agonists at nerve terminals only takes place after prolonged receptor activation.
This article is part of a themed section on Opioids: New Pathways to Functional Selectivity. To view the other articles in this section visit http://dx.doi.org/10.1111/bph.2015.172.issue-2. Background and Purpose The majority of studies examining desensitization of the mu -opioid receptor (MOR) have examined those located at cell bodies. However, MORs are extensively expressed at nerve terminals throughout the mammalian nervous system. This study is designed to investigate agonist-induced MOR desensitization at nerve terminals in the mouse ventral tegmental area (VTA). Experimental Approach MOR function was measured in mature mouse brain slices containing the VTA using whole-cell patch-clamp electrophysiology. Presynaptic MOR function was isolated from postsynaptic function and the functional selectivity, time-dependence and mechanisms of agonist-induced MOR desensitization were examined. Key Results MORs located at GABAergic nerve terminals in the VTA were completely resistant to rapid desensitization induced by the high-efficacy agonists DAMGO and Met-enkephalin. MORs located postsynaptically on GABAergic cell bodies readily underwent rapid desensitization in response to DAMGO. However, after prolonged (>7h) treatment with Met-enkephalin, profound homologous MOR desensitization was observed. Morphine could induce rapid MOR desensitization at nerve terminals when PKC was activated. Conclusions and Implications Agonist-induced MOR desensitization in GABAergic neurons in the VTA is compartment-selective as well as agonist-selective. When MORs are located at cell bodies, higher-efficacy agonists induce greater levels of rapid desensitization than lower-efficacy agonists. However, the converse is true at nerve terminals where agonists that induce MOR desensitization via PKC are capable of rapid agonist-induced desensitization while higher-efficacy agonists are not. MOR desensitization induced by higher-efficacy agonists at nerve terminals only takes place after prolonged receptor activation. Linked Articles This article is part of a themed section on Opioids: New Pathways to Functional Selectivity. To view the other articles in this section visit http://dx.doi.org/10.1111/bph.2015.172.issue-2 Background and Purpose The majority of studies examining desensitization of the μ‐opioid receptor ( MOR ) have examined those located at cell bodies. However, MOR s are extensively expressed at nerve terminals throughout the mammalian nervous system. This study is designed to investigate agonist‐induced MOR desensitization at nerve terminals in the mouse ventral tegmental area ( VTA ). Experimental Approach MOR function was measured in mature mouse brain slices containing the VTA using whole‐cell patch‐clamp electrophysiology. Presynaptic MOR function was isolated from postsynaptic function and the functional selectivity, time‐dependence and mechanisms of agonist‐induced MOR desensitization were examined. Key Results MOR s located at GABA ergic nerve terminals in the VTA were completely resistant to rapid desensitization induced by the high‐efficacy agonists DAMGO and Met‐enkephalin. MOR s located postsynaptically on GABA ergic cell bodies readily underwent rapid desensitization in response to DAMGO . However, after prolonged (>7 h) treatment with Met‐enkephalin, profound homologous MOR desensitization was observed. Morphine could induce rapid MOR desensitization at nerve terminals when PKC was activated. Conclusions and Implications Agonist‐induced MOR desensitization in GABA ergic neurons in the VTA is compartment‐selective as well as agonist‐selective. When MOR s are located at cell bodies, higher‐efficacy agonists induce greater levels of rapid desensitization than lower‐efficacy agonists. However, the converse is true at nerve terminals where agonists that induce MOR desensitization via PKC are capable of rapid agonist‐induced desensitization while higher‐efficacy agonists are not. MOR desensitization induced by higher‐efficacy agonists at nerve terminals only takes place after prolonged receptor activation. Linked Articles This article is part of a themed section on Opioids: New Pathways to Functional Selectivity. To view the other articles in this section visit http://dx.doi.org/10.1111/bph.2015.172.issue-2 BACKGROUND AND PURPOSEThe majority of studies examining desensitization of the μ-opioid receptor (MOR) have examined those located at cell bodies. However, MORs are extensively expressed at nerve terminals throughout the mammalian nervous system. This study is designed to investigate agonist-induced MOR desensitization at nerve terminals in the mouse ventral tegmental area (VTA). EXPERIMENTAL APPROACHMOR function was measured in mature mouse brain slices containing the VTA using whole-cell patch-clamp electrophysiology. Presynaptic MOR function was isolated from postsynaptic function and the functional selectivity, time-dependence and mechanisms of agonist-induced MOR desensitization were examined. KEY RESULTSMORs located at GABAergic nerve terminals in the VTA were completely resistant to rapid desensitization induced by the high-efficacy agonists DAMGO and Met-enkephalin. MORs located postsynaptically on GABAergic cell bodies readily underwent rapid desensitization in response to DAMGO. However, after prolonged (>7 h) treatment with Met-enkephalin, profound homologous MOR desensitization was observed. Morphine could induce rapid MOR desensitization at nerve terminals when PKC was activated. CONCLUSIONS AND IMPLICATIONSAgonist-induced MOR desensitization in GABAergic neurons in the VTA is compartment-selective as well as agonist-selective. When MORs are located at cell bodies, higher-efficacy agonists induce greater levels of rapid desensitization than lower-efficacy agonists. However, the converse is true at nerve terminals where agonists that induce MOR desensitization via PKC are capable of rapid agonist-induced desensitization while higher-efficacy agonists are not. MOR desensitization induced by higher-efficacy agonists at nerve terminals only takes place after prolonged receptor activation. LINKED ARTICLESThis article is part of a themed section on Opioids: New Pathways to Functional Selectivity. To view the other articles in this section visit http://dx.doi.org/10.1111/bph.2015.172.issue-2. Background and Purpose The majority of studies examining desensitization of the μ‐opioid receptor (MOR) have examined those located at cell bodies. However, MORs are extensively expressed at nerve terminals throughout the mammalian nervous system. This study is designed to investigate agonist‐induced MOR desensitization at nerve terminals in the mouse ventral tegmental area (VTA). Experimental Approach MOR function was measured in mature mouse brain slices containing the VTA using whole‐cell patch‐clamp electrophysiology. Presynaptic MOR function was isolated from postsynaptic function and the functional selectivity, time‐dependence and mechanisms of agonist‐induced MOR desensitization were examined. Key Results MORs located at GABAergic nerve terminals in the VTA were completely resistant to rapid desensitization induced by the high‐efficacy agonists DAMGO and Met‐enkephalin. MORs located postsynaptically on GABAergic cell bodies readily underwent rapid desensitization in response to DAMGO. However, after prolonged (>7 h) treatment with Met‐enkephalin, profound homologous MOR desensitization was observed. Morphine could induce rapid MOR desensitization at nerve terminals when PKC was activated. Conclusions and Implications Agonist‐induced MOR desensitization in GABAergic neurons in the VTA is compartment‐selective as well as agonist‐selective. When MORs are located at cell bodies, higher‐efficacy agonists induce greater levels of rapid desensitization than lower‐efficacy agonists. However, the converse is true at nerve terminals where agonists that induce MOR desensitization via PKC are capable of rapid agonist‐induced desensitization while higher‐efficacy agonists are not. MOR desensitization induced by higher‐efficacy agonists at nerve terminals only takes place after prolonged receptor activation. Linked Articles This article is part of a themed section on Opioids: New Pathways to Functional Selectivity. To view the other articles in this section visit http://dx.doi.org/10.1111/bph.2015.172.issue-2 Background and Purpose The majority of studies examining desensitization of the µ-opioid receptor (MOR) have examined those located at cell bodies. However, MORs are extensively expressed at nerve terminals throughout the mammalian nervous system. This study is designed to investigate agonist-induced MOR desensitization at nerve terminals in the mouse ventral tegmental area (VTA). Experimental Approach MOR function was measured in mature mouse brain slices containing the VTA using whole-cell patch-clamp electrophysiology. Presynaptic MOR function was isolated from postsynaptic function and the functional selectivity, time-dependence and mechanisms of agonist-induced MOR desensitization were examined. Key Results MORs located at GABAergic nerve terminals in the VTA were completely resistant to rapid desensitization induced by the high-efficacy agonists DAMGO and Met-enkephalin. MORs located postsynaptically on GABAergic cell bodies readily underwent rapid desensitization in response to DAMGO. However, after prolonged (>7h) treatment with Met-enkephalin, profound homologous MOR desensitization was observed. Morphine could induce rapid MOR desensitization at nerve terminals when PKC was activated. Conclusions and Implications Agonist-induced MOR desensitization in GABAergic neurons in the VTA is compartment-selective as well as agonist-selective. When MORs are located at cell bodies, higher-efficacy agonists induce greater levels of rapid desensitization than lower-efficacy agonists. However, the converse is true at nerve terminals where agonists that induce MOR desensitization via PKC are capable of rapid agonist-induced desensitization while higher-efficacy agonists are not. MOR desensitization induced by higher-efficacy agonists at nerve terminals only takes place after prolonged receptor activation. Linked Articles This article is part of a themed section on Opioids: New Pathways to Functional Selectivity. To view the other articles in this section visit http://dx.doi.org/10.1111/bph.2015.172.issue-2 |
Author | Bailey, C P Lowe, J D |
Author_xml | – sequence: 1 givenname: J D surname: Lowe fullname: Lowe, J D organization: University of Bristol – sequence: 2 givenname: C P surname: Bailey fullname: Bailey, C P organization: University of Bath |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/24467517$$D View this record in MEDLINE/PubMed |
BookMark | eNqNks9u1DAQxi1URLcLB14AWeICh7R2_tjOBalUlCJVggOcLceedF0ldrCdRcuJOxceiGfgIXgSvKRUgISELzPy_PTNfPYcoQPnHSD0kJJjms9JN22OaclIcwetaM1Z0VSCHqAVIYQXlApxiI5ivCYkF3lzDx2Wdc14Q_kKfT6fnU7WOzXgCAPkfGvTDitncLIjfP_0xcAEzoDTgH2Pv33NV36y3hocQMOUfMAGIrhok_2o9lpYJewgbAEnCKPN2hFbh9MG8OjnCHgLLoXcMcHVmNOcqQDqPrrbZxQe3MQ1enf-4u3ZRXH5-uWrs9PLQmdvTVELMC3vBNGgGChhuKKk6hmIruQ9sLLpdCtqLjhjnLa6YVSbDjrOueZaVNUaPVt0p7kbwehlGDkFO6qwk15Z-WfF2Y288ltZl23ZMpoFntwIBP9-hpjkaKOGYVAOsj9JWVu3TPCy_A-0JrUoWXawRo__Qq_9HPaPl6mqbYigOa7R04XSwccYoL-dmxK53waZt0H-3IbMPvrd6C356_szcLIAH-wAu38ryedvLhbJHzjOxnQ |
CitedBy_id | crossref_primary_10_7554_eLife_81119 crossref_primary_10_1124_mol_119_119321 crossref_primary_10_1016_j_neuropharm_2022_109408 crossref_primary_10_1016_j_neuron_2019_11_016 crossref_primary_10_1038_s41598_017_10360_8 crossref_primary_10_1124_mol_117_109603 crossref_primary_10_1002_pro_3872 crossref_primary_10_1016_j_tins_2024_05_008 crossref_primary_10_1159_000381457 crossref_primary_10_1111_bph_13028 crossref_primary_10_3389_fnmol_2022_919773 crossref_primary_10_1002_mco2_148 crossref_primary_10_1016_j_biopsych_2016_12_022 crossref_primary_10_1016_j_neuroscience_2016_01_047 crossref_primary_10_1016_j_neuroscience_2023_05_026 crossref_primary_10_1016_j_peptides_2016_12_004 crossref_primary_10_3390_cells9112400 crossref_primary_10_7554_eLife_81298 crossref_primary_10_1111_bph_12633 crossref_primary_10_1111_bph_14547 crossref_primary_10_1016_j_pharmthera_2021_107961 |
Cites_doi | 10.1523/JNEUROSCI.4654-10.2011 10.1113/jphysiol.2011.210807 10.1146/annurev.pharmtox.38.1.201 10.1124/mol.106.022376 10.1073/pnas.1105418108 10.1124/mol.104.004747 10.1523/JNEUROSCI.11-08-02574.1991 10.1124/mol.112.081547 10.1124/mol.110.066613 10.1073/pnas.0136822100 10.1523/JNEUROSCI.23-33-10515.2003 10.1038/sj.bjp.0707604 10.1113/jphysiol.1992.sp019136 10.1073/pnas.95.17.9914 10.1046/j.1471-4159.1995.65041636.x 10.1113/jphysiol.2002.023093 10.1523/JNEUROSCI.12-02-00483.1992 10.1111/j.1476-5381.2011.01382.x 10.1038/37610 10.1124/mol.110.069096 10.1073/pnas.1000751107 10.1073/pnas.072075399 10.1523/JNEUROSCI.5251-03.2004 10.1113/jphysiol.2006.117069 10.1523/JNEUROSCI.22-04-01248.2002 10.1016/S0028-3908(02)00061-8 10.1111/j.1476-5381.2009.00140.x 10.1111/ejn.12003 10.1016/j.devcel.2006.04.002 10.1016/0024-3205(81)90148-X 10.1124/mol.58.2.388 10.1523/JNEUROSCI.17-02-00796.1997 10.1124/pr.112.005942 10.1016/j.neuron.2004.12.049 10.1111/j.1476-5381.2010.00872.x 10.1523/JNEUROSCI.1227-12.2012 10.1523/JNEUROSCI.1504-11.2011 10.1111/bph.12447 10.1523/JNEUROSCI.4570-11.2011 10.1523/JNEUROSCI.2304-11.2011 10.1074/jbc.M100305200 10.1523/JNEUROSCI.22-13-05769.2002 10.1016/S0306-4522(96)00444-7 10.1016/0006-8993(94)01391-T 10.1111/bph.12441 10.1124/jpet.110.172643 10.1053/j.gastro.2010.11.005 10.1111/bph.12445 10.1016/j.conb.2011.01.007 10.1074/jbc.M110.177089 10.1016/S1044-7431(03)00173-8 10.1021/bi991205r 10.1111/j.1476-5381.2010.00873.x |
ContentType | Journal Article |
Copyright | 2014 The Authors. British Journal of Pharmacology published by John Wiley & Sons Ltd on behalf of The British Pharmacological Society. Copyright © 2015 The British Pharmacological Society Copyright © 2015 The British Pharmacological Society 2015 |
Copyright_xml | – notice: 2014 The Authors. British Journal of Pharmacology published by John Wiley & Sons Ltd on behalf of The British Pharmacological Society. – notice: Copyright © 2015 The British Pharmacological Society – notice: Copyright © 2015 The British Pharmacological Society 2015 |
DBID | 24P WIN CGR CUY CVF ECM EIF NPM AAYXX CITATION 7QP 7TK K9. NAPCQ 7X8 5PM |
DOI | 10.1111/bph.12605 |
DatabaseName | Wiley Online Library Open Access Wiley Online Library Open Access Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef Calcium & Calcified Tissue Abstracts Neurosciences Abstracts ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium Calcium & Calcified Tissue Abstracts Neurosciences Abstracts MEDLINE - Academic |
DatabaseTitleList | MEDLINE Neurosciences Abstracts CrossRef MEDLINE - Academic ProQuest Health & Medical Complete (Alumni) |
Database_xml | – sequence: 1 dbid: 24P name: Wiley Online Library Open Access url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html sourceTypes: Publisher – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1476-5381 |
EndPage | 481 |
ExternalDocumentID | 3534523781 10_1111_bph_12605 24467517 BPH12605 |
Genre | article Research Support, Non-U.S. Gov't Journal Article |
GrantInformation_xml | – fundername: MRC project grant funderid: G0701486 – fundername: Wellcome Trust Value in People – fundername: Medical Research Council grantid: G0701486 – fundername: Wellcome Trust |
GroupedDBID | --- .3N .55 .GJ 05W 0R~ 1OC 23N 24P 2WC 31~ 33P 36B 3O- 3SF 3V. 4.4 52U 52V 53G 5GY 6J9 7RV 7X7 8-0 8-1 88E 8AO 8FE 8FH 8FI 8FJ 8R4 8R5 8UM A00 AAESR AAEVG AAHHS AANLZ AAONW AASGY AAXRX AAZKR ABCUV ABDBF ABPVW ABQWH ABUWG ABXGK ACAHQ ACCFJ ACCZN ACFBH ACGFO ACGFS ACGOF ACMXC ACPOU ACPRK ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN ADZOD AEEZP AEGXH AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFFPM AFGKR AFKRA AFPWT AFRAH AFZJQ AHBTC AHMBA AIACR AIAGR AITYG AIURR AIWBW AJBDE ALAGY ALIPV ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB AOIJS ATUGU AZBYB AZVAB B0M BAFTC BAWUL BBNVY BENPR BFHJK BHBCM BHPHI BKEYQ BMXJE BPHCQ BRXPI BVXVI C45 CAG CCPQU COF CS3 DCZOG DIK DRFUL DRMAN DRSTM DU5 E3Z EAD EAP EAS EBC EBD EBS ECV EJD EMB EMK EMOBN ENC ESX EX3 F5P FUBAC FYUFA G-S GODZA GX1 H.X HCIFZ HGLYW HMCUK HYE HZ~ J5H KBYEO LATKE LEEKS LH4 LITHE LK8 LOXES LSO LUTES LW6 LYRES M1P M7P MEWTI MK0 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM MY~ N9A NAPCQ NF~ O66 O9- OIG OK1 OVD P2P P2W P4E PQQKQ PROAC PSQYO Q.N Q2X QB0 RIG ROL RPM RWI SJN SUPJJ SV3 TEORI TR2 TUS UKHRP UPT WBKPD WH7 WHWMO WIH WIJ WIK WIN WOHZO WOW WVDHM WXSBR X7M XV2 Y6R YHG ZGI ZXP ZZTAW ~8M ~S- CGR CUY CVF ECM EIF NPM AAYXX CITATION 7QP 7TK K9. 7X8 5PM |
ID | FETCH-LOGICAL-c4765-48ed97b80cea6ea8d7a103f6e8b27fe625bc98478766719c561cdbeb777c7c833 |
IEDL.DBID | RPM |
ISSN | 0007-1188 |
IngestDate | Tue Sep 17 21:14:24 EDT 2024 Fri Aug 16 01:28:31 EDT 2024 Fri Aug 16 11:39:20 EDT 2024 Thu Oct 10 22:12:26 EDT 2024 Fri Aug 23 01:30:32 EDT 2024 Sat Sep 28 08:13:01 EDT 2024 Sat Aug 24 00:50:51 EDT 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 2 |
Keywords | nerve terminal opioid PKC GPCR kinase (GRK) desensitization tolerance morphine opiate ventral tegmental area (VTA) |
Language | English |
License | Attribution 2014 The Authors. British Journal of Pharmacology published by John Wiley & Sons Ltd on behalf of The British Pharmacological Society. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c4765-48ed97b80cea6ea8d7a103f6e8b27fe625bc98478766719c561cdbeb777c7c833 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4292961/ |
PMID | 24467517 |
PQID | 1639508116 |
PQPubID | 42104 |
PageCount | 13 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_4292961 proquest_miscellaneous_1694968722 proquest_miscellaneous_1640482610 proquest_journals_1639508116 crossref_primary_10_1111_bph_12605 pubmed_primary_24467517 wiley_primary_10_1111_bph_12605_BPH12605 |
PublicationCentury | 2000 |
PublicationDate | January 2015 |
PublicationDateYYYYMMDD | 2015-01-01 |
PublicationDate_xml | – month: 01 year: 2015 text: January 2015 |
PublicationDecade | 2010 |
PublicationPlace | England |
PublicationPlace_xml | – name: England – name: London – name: Oxford, UK |
PublicationTitle | British journal of pharmacology |
PublicationTitleAlternate | Br J Pharmacol |
PublicationYear | 2015 |
Publisher | Blackwell Publishing Ltd |
Publisher_xml | – name: Blackwell Publishing Ltd |
References | 2006; 70 2004; 66 1987; 32 2010; 107 2013; 65 1991; 11 2002; 13 2013b; 170 2002; 99 2004; 24 2006; 577 2009; 158 1992a; 12 1992b; 450 2000; 58 2002; 42 1995; 65 1997; 17 2011; 21 1997; 390 1998; 95 1998; 54 2008; 153 2011; 286 2011; 164 2010; 78 2012; 82 2002b; 544 2006; 10 2011; 31 2011; 79 1981; 28 2010; 160 1995; 672 2012; 36 2012; 32 2005; 45 2011; 589 2001; 276 1998; 38 2002a; 22 2011; 108 1997; 77 2010; 335 1999; 38 2003; 24 2011; 140 2013; 171 2003; 100 2013a; 170 2003; 23 e_1_2_11_32_1 e_1_2_11_55_1 e_1_2_11_30_1 e_1_2_11_36_1 e_1_2_11_51_1 e_1_2_11_13_1 e_1_2_11_34_1 e_1_2_11_53_1 e_1_2_11_11_1 e_1_2_11_29_1 e_1_2_11_6_1 e_1_2_11_27_1 e_1_2_11_48_1 e_1_2_11_2_1 Christie MJ (e_1_2_11_17_1) 1987; 32 e_1_2_11_20_1 e_1_2_11_45_1 e_1_2_11_47_1 e_1_2_11_24_1 e_1_2_11_41_1 e_1_2_11_8_1 e_1_2_11_43_1 e_1_2_11_15_1 e_1_2_11_38_1 Alvarez VA (e_1_2_11_4_1) 2002; 13 e_1_2_11_19_1 Harris GC (e_1_2_11_22_1) 1991; 11 e_1_2_11_50_1 e_1_2_11_10_1 e_1_2_11_56_1 e_1_2_11_14_1 e_1_2_11_35_1 e_1_2_11_52_1 e_1_2_11_12_1 e_1_2_11_33_1 e_1_2_11_54_1 e_1_2_11_28_1 e_1_2_11_5_1 e_1_2_11_26_1 e_1_2_11_3_1 e_1_2_11_49_1 Bailey CP (e_1_2_11_7_1) 2003; 23 e_1_2_11_21_1 e_1_2_11_44_1 e_1_2_11_46_1 e_1_2_11_25_1 e_1_2_11_40_1 e_1_2_11_9_1 e_1_2_11_23_1 e_1_2_11_42_1 e_1_2_11_18_1 e_1_2_11_16_1 Kovoor A (e_1_2_11_31_1) 1998; 54 e_1_2_11_37_1 e_1_2_11_39_1 |
References_xml | – volume: 77 start-page: 155 year: 1997 end-page: 166 article-title: A subset of ventral tegmental area neurons is inhibited by dopamine, 5‐hydroxytryptamine and opioids publication-title: Neuroscience – volume: 65 start-page: 1636 year: 1995 end-page: 1645 article-title: Phosphorylation and agonist‐specific intracellular trafficking of an epitope‐tagged mu‐opioid receptor expressed in HEK 293 cells publication-title: J Neurochem – volume: 23 start-page: 10515 year: 2003 end-page: 10520 article-title: Mu‐opioid receptor desensitization in mature rat neurons: lack of interaction between DAMGO and morphine publication-title: J Neurosci – volume: 160 start-page: 1577 year: 2010 end-page: 1579 article-title: Animal research: Reporting experiments: the ARRIVE guidelines publication-title: Br J Pharmacol – volume: 170 start-page: 1607 year: 2013b end-page: 1651 article-title: The Concise Guide to PHARMACOLOGY 2013/14: Ion Channels publication-title: Br J Pharmacol – volume: 450 start-page: 455 year: 1992b end-page: 468 article-title: Two types of neurone in the rat ventral tegmental area and their synaptic inputs publication-title: J Physiol – volume: 24 start-page: 2806 year: 2004 end-page: 2812 article-title: Spinal G‐protein‐gated K + channels formed by GIRK1 and GIRK2 subunits modulate thermal nociception and contribute to morphine analgesia publication-title: J Neurosci – volume: 45 start-page: 433 year: 2005 end-page: 445 article-title: GABA transporter currents activated by protein kinase A excite midbrain neurons during opioid withdrawal publication-title: Neuron – volume: 21 start-page: 275 year: 2011 end-page: 282 article-title: Differential regulation of spontaneous and evoked neurotransmitter release at central synapses publication-title: Curr Opin Neurobiol – volume: 32 start-page: 633 year: 1987 end-page: 638 article-title: Cellular mechanisms of opioid tolerance: studies in single brain neurons publication-title: Mol Pharmacol – volume: 31 start-page: 13890 year: 2011 end-page: 13896 article-title: Analgesic tolerance to high‐efficacy agonists but not to morphine is diminished in phosphorylation‐deficient S375A μ‐opioid receptor knock‐in mice publication-title: J Neurosci – volume: 66 start-page: 1592 year: 2004 end-page: 1598 article-title: Protein kinase C activation enhances morphine‐induced rapid desensitization of mu‐opioid receptors in mature rat locus ceruleus neurons publication-title: Mol Pharmacol – volume: 24 start-page: 517 year: 2003 end-page: 523 article-title: Two distinct forms of desensitisation of G‐protein coupled inwardly rectifying potassium currents evoked by alkaloid and peptide μ‐opioid receptor agonists publication-title: Mol Cell Neurosci – volume: 42 start-page: 1065 year: 2002 end-page: 1078 article-title: Presynaptic mu‐opioid receptors regulate a late step of the secretory process in rat ventral tegmental area GABAergic neurons publication-title: Neuropharmacology – volume: 31 start-page: 281 year: 2011 end-page: 288 article-title: Differential expression and sensitivity of presynaptic and postsynaptic opioid receptors regulating hypothalamic proopiomelanocortin neurons publication-title: J Neurosci – volume: 12 start-page: 483 year: 1992a end-page: 488 article-title: Opioids excite dopamine neurons by hyperpolarization of local interneurons publication-title: J Neurosci – volume: 28 start-page: 551 year: 1981 end-page: 555 article-title: Intracranial self‐administration of morphine into the ventral tegmental area in rats publication-title: Life Sci – volume: 140 start-page: 618 year: 2011 end-page: 626 article-title: Morphine induces μ opioid receptor endocytosis in guinea pig enteric neurons following prolonged receptor activation publication-title: Gastroenterology – volume: 17 start-page: 796 year: 1997 end-page: 803 article-title: Increased probability of GABA release during withdrawal from morphine publication-title: J Neurosci – volume: 58 start-page: 388 year: 2000 end-page: 398 article-title: Receptor density and recycling affect the rate of agonist‐induced desensitization of mu‐opioid receptor publication-title: Mol Pharmacol – volume: 107 start-page: 11608 year: 2010 end-page: 11613 article-title: Ligand‐directed c‐Jun N‐terminal kinase activation disrupts opioid receptor signaling publication-title: Proc Natl Acad Sci U S A – volume: 164 start-page: 298 year: 2011 end-page: 307 article-title: Agonist‐selective patterns of μ‐opioid receptor phosphorylation revealed by phosphosite‐specific antibodies publication-title: Br J Pharmacol – volume: 31 start-page: 7811 year: 2011 end-page: 7816 article-title: Nucleus accumbens medium spiny neurons target non‐dopaminergic neurons in the ventral tegmental area publication-title: J Neurosci – volume: 100 start-page: 271 year: 2003 end-page: 276 article-title: Contribution of GIRK2‐mediated postsynaptic signaling to opiate and alpha 2‐adrenergic analgesia and analgesic sex differences publication-title: Proc Natl Acad Sci U S A – volume: 54 start-page: 704 year: 1998 end-page: 711 article-title: Agonist induced homologous desensitization of mu‐opioid receptors mediated by G protein‐coupled receptor kinases is dependent on agonist efficacy publication-title: Mol Pharmacol – volume: 589 start-page: 3775 year: 2011 end-page: 3787 article-title: Distinct cellular properties of identified dopaminergic and GABAergic neurons in the mouse ventral tegmental area publication-title: J Physiol – volume: 82 start-page: 983 year: 2012 end-page: 992 article-title: Morphine desensitization and cellular tolerance are distinguished in rat locus ceruleus neurons publication-title: Mol Pharmacol – volume: 38 start-page: 201 year: 1998 end-page: 207 article-title: Presynaptic receptors publication-title: Annu Rev Pharmacol Toxicol – volume: 13 start-page: 5769 year: 2002 end-page: 5776 article-title: mu‐Opioid receptors: ligand‐dependent activation of potassium conductance, desensitization, and internalization publication-title: J Neurosci – volume: 170 start-page: 1459 year: 2013a end-page: 1581 article-title: The Concise Guide to PHARMACOLOGY 2013/14: G Protein‐Coupled Receptors publication-title: Br J Pharmacol – volume: 577 start-page: 907 year: 2006 end-page: 924 article-title: The ventral tegmental area revisited: is there an electrophysiological marker for dopaminergic neurons? publication-title: J Physiol – volume: 22 start-page: 1248 year: 2002a end-page: 1255 article-title: Differential desensitization of responses mediated by presynaptic and postsynaptic A1 adenosine receptors publication-title: J Neurosci – volume: 672 start-page: 261 year: 1995 end-page: 275 article-title: Ultrastructural relationships between terminals immunoreactive for enkephalin, GABA, or both transmitters in the rat ventral tegmental area publication-title: Brain Res – volume: 70 start-page: 676 year: 2006 end-page: 685 article-title: Agonist‐selective mechanisms of mu‐opioid receptor desensitization in human embryonic kidney 293 cells publication-title: Mol Pharmacol – volume: 10 start-page: 839 year: 2006 end-page: 850 article-title: Dynasore, a cell‐permeable inhibitor of dynamin publication-title: Dev Cell – volume: 79 start-page: 768 year: 2011 end-page: 775 article-title: Protein kinase C‐mediated phosphorylation of the μ‐opioid receptor and its effects on receptor signaling publication-title: Mol Pharmacol – volume: 38 start-page: 14286 year: 1999 end-page: 14293 article-title: Synthesis of a stable form of tertiapin: a high‐affinity inhibitor for inward‐rectifier K+ channels publication-title: Biochemistry – volume: 153 start-page: S379 issue: Suppl. 1 year: 2008 end-page: S388 article-title: Agonist‐selective mechanisms of GPCR desensitization publication-title: Br J Pharmacol – volume: 171 start-page: 253 year: 2013 end-page: 264 article-title: G protein‐gated inwardly rectifying potassium (GIRK) channels play a primary role in the antinociceptive effect of oxycodone, but not morphine, at supraspinal sites publication-title: Br J Pharmacol – volume: 335 start-page: 674 year: 2010 end-page: 680 article-title: Tolerance to the antinociceptive effect of morphine in the absence of short‐term presynaptic desensitization in rat periaqueductal gray neurons publication-title: J Pharmacol Exp Ther – volume: 99 start-page: 4674 year: 2002 end-page: 4679 article-title: Desensitization of mu‐opioid receptor‐evoked potassium currents: initiation at the receptor, expression at the effector publication-title: Proc Natl Acad Sci U S A – volume: 390 start-page: 611 year: 1997 end-page: 614 article-title: How opioids inhibit GABA‐mediated neurotransmission publication-title: Nature – volume: 65 start-page: 223 year: 2013 end-page: 254 article-title: Regulation of μ‐opioid receptors: desensitization, phosphorylation, internalization, and tolerance publication-title: Pharmacol Rev – volume: 108 start-page: 16446 year: 2011 end-page: 16450 article-title: Neuronal circuits underlying acute morphine action on dopamine neurons publication-title: Proc Natl Acad Sci U S A – volume: 36 start-page: 3636 year: 2012 end-page: 3642 article-title: μ‐Opioid receptor desensitization: homologous or heterologous? publication-title: Eur J Neurosci – volume: 286 start-page: 12724 year: 2011 end-page: 12733 article-title: Modulating micro‐opioid receptor phosphorylation switches agonist‐dependent signaling as reflected in PKCepsilon activation and dendritic spine stability publication-title: J Biol Chem – volume: 276 start-page: 31408 year: 2001 end-page: 31414 article-title: C‐terminal splice variants of the mouse mu‐opioid receptor differ in morphine‐induced internalization and receptor resensitization publication-title: J Biol Chem – volume: 32 start-page: 10192 year: 2012 end-page: 10200 article-title: Multiple inhibitory G‐protein‐coupled receptors resist acute desensitization in the presynaptic but not postsynaptic compartments of neurons publication-title: J Neurosci – volume: 31 start-page: 17729 year: 2011 end-page: 17735 article-title: Opioid‐sensitive GABA inputs from rostromedial tegmental nucleus synapse onto midbrain dopamine neurons publication-title: J Neurosci – volume: 78 start-page: 756 year: 2010 end-page: 766 article-title: μ‐opioid receptors: correlation of agonist efficacy for signalling with ability to activate internalization publication-title: Mol Pharmacol – volume: 95 start-page: 9914 year: 1998 end-page: 9919 article-title: Morphine‐activated opioid receptors elude desensitization by beta‐arrestin publication-title: Proc Natl Acad Sci U S A – volume: 158 start-page: 157 year: 2009 end-page: 164 article-title: Involvement of PKC alpha and G‐protein‐coupled receptor kinase 2 in agonist‐selective desensitization of mu‐opioid receptors in mature brain neurons publication-title: Br J Pharmacol – volume: 544 start-page: 459 year: 2002b end-page: 467 article-title: GABA(B) receptor activation desensitizes postsynaptic GABA(B) and A(1) adenosine responses in rat hippocampal neurones publication-title: J Physiol – volume: 160 start-page: 1573 year: 2010 end-page: 1576 article-title: Guidelines for reporting experiments involving animals: the ARRIVE guidelines publication-title: Br J Pharmacol – volume: 11 start-page: 2574 year: 1991 end-page: 2581 article-title: Transient homologous mu‐opioid receptor desensitization in rat locus coeruleus neurons publication-title: J Neurosci – ident: e_1_2_11_47_1 doi: 10.1523/JNEUROSCI.4654-10.2011 – ident: e_1_2_11_16_1 doi: 10.1113/jphysiol.2011.210807 – ident: e_1_2_11_42_1 doi: 10.1146/annurev.pharmtox.38.1.201 – ident: e_1_2_11_25_1 doi: 10.1124/mol.106.022376 – ident: e_1_2_11_23_1 doi: 10.1073/pnas.1105418108 – ident: e_1_2_11_8_1 doi: 10.1124/mol.104.004747 – volume: 11 start-page: 2574 year: 1991 ident: e_1_2_11_22_1 article-title: Transient homologous mu‐opioid receptor desensitization in rat locus coeruleus neurons publication-title: J Neurosci doi: 10.1523/JNEUROSCI.11-08-02574.1991 contributor: fullname: Harris GC – ident: e_1_2_11_33_1 doi: 10.1124/mol.112.081547 – ident: e_1_2_11_40_1 doi: 10.1124/mol.110.066613 – ident: e_1_2_11_43_1 doi: 10.1073/pnas.0136822100 – volume: 23 start-page: 10515 year: 2003 ident: e_1_2_11_7_1 article-title: Mu‐opioid receptor desensitization in mature rat neurons: lack of interaction between DAMGO and morphine publication-title: J Neurosci doi: 10.1523/JNEUROSCI.23-33-10515.2003 contributor: fullname: Bailey CP – ident: e_1_2_11_28_1 doi: 10.1038/sj.bjp.0707604 – ident: e_1_2_11_27_1 doi: 10.1113/jphysiol.1992.sp019136 – ident: e_1_2_11_53_1 doi: 10.1073/pnas.95.17.9914 – ident: e_1_2_11_5_1 doi: 10.1046/j.1471-4159.1995.65041636.x – ident: e_1_2_11_52_1 doi: 10.1113/jphysiol.2002.023093 – ident: e_1_2_11_26_1 doi: 10.1523/JNEUROSCI.12-02-00483.1992 – ident: e_1_2_11_18_1 doi: 10.1111/j.1476-5381.2011.01382.x – ident: e_1_2_11_50_1 doi: 10.1038/37610 – ident: e_1_2_11_19_1 doi: 10.1124/mol.110.069096 – ident: e_1_2_11_41_1 doi: 10.1073/pnas.1000751107 – volume: 54 start-page: 704 year: 1998 ident: e_1_2_11_31_1 article-title: Agonist induced homologous desensitization of mu‐opioid receptors mediated by G protein‐coupled receptor kinases is dependent on agonist efficacy publication-title: Mol Pharmacol contributor: fullname: Kovoor A – ident: e_1_2_11_11_1 doi: 10.1073/pnas.072075399 – ident: e_1_2_11_38_1 doi: 10.1523/JNEUROSCI.5251-03.2004 – ident: e_1_2_11_37_1 doi: 10.1113/jphysiol.2006.117069 – ident: e_1_2_11_51_1 doi: 10.1523/JNEUROSCI.22-04-01248.2002 – ident: e_1_2_11_10_1 doi: 10.1016/S0028-3908(02)00061-8 – ident: e_1_2_11_9_1 doi: 10.1111/j.1476-5381.2009.00140.x – ident: e_1_2_11_34_1 doi: 10.1111/ejn.12003 – ident: e_1_2_11_36_1 doi: 10.1016/j.devcel.2006.04.002 – ident: e_1_2_11_14_1 doi: 10.1016/0024-3205(81)90148-X – ident: e_1_2_11_32_1 doi: 10.1124/mol.58.2.388 – volume: 32 start-page: 633 year: 1987 ident: e_1_2_11_17_1 article-title: Cellular mechanisms of opioid tolerance: studies in single brain neurons publication-title: Mol Pharmacol contributor: fullname: Christie MJ – ident: e_1_2_11_13_1 doi: 10.1523/JNEUROSCI.17-02-00796.1997 – ident: e_1_2_11_54_1 doi: 10.1124/pr.112.005942 – ident: e_1_2_11_6_1 doi: 10.1016/j.neuron.2004.12.049 – ident: e_1_2_11_29_1 doi: 10.1111/j.1476-5381.2010.00872.x – ident: e_1_2_11_46_1 doi: 10.1523/JNEUROSCI.1227-12.2012 – ident: e_1_2_11_55_1 doi: 10.1523/JNEUROSCI.1504-11.2011 – ident: e_1_2_11_3_1 doi: 10.1111/bph.12447 – ident: e_1_2_11_39_1 doi: 10.1523/JNEUROSCI.4570-11.2011 – ident: e_1_2_11_21_1 doi: 10.1523/JNEUROSCI.2304-11.2011 – ident: e_1_2_11_30_1 doi: 10.1074/jbc.M100305200 – volume: 13 start-page: 5769 year: 2002 ident: e_1_2_11_4_1 article-title: mu‐Opioid receptors: ligand‐dependent activation of potassium conductance, desensitization, and internalization publication-title: J Neurosci doi: 10.1523/JNEUROSCI.22-13-05769.2002 contributor: fullname: Alvarez VA – ident: e_1_2_11_15_1 doi: 10.1016/S0306-4522(96)00444-7 – ident: e_1_2_11_49_1 doi: 10.1016/0006-8993(94)01391-T – ident: e_1_2_11_44_1 doi: 10.1111/bph.12441 – ident: e_1_2_11_20_1 doi: 10.1124/jpet.110.172643 – ident: e_1_2_11_45_1 doi: 10.1053/j.gastro.2010.11.005 – ident: e_1_2_11_2_1 doi: 10.1111/bph.12445 – ident: e_1_2_11_48_1 doi: 10.1016/j.conb.2011.01.007 – ident: e_1_2_11_56_1 doi: 10.1074/jbc.M110.177089 – ident: e_1_2_11_12_1 doi: 10.1016/S1044-7431(03)00173-8 – ident: e_1_2_11_24_1 doi: 10.1021/bi991205r – ident: e_1_2_11_35_1 doi: 10.1111/j.1476-5381.2010.00873.x |
SSID | ssj0014775 |
Score | 2.3040342 |
Snippet | Background and Purpose
The majority of studies examining desensitization of the μ‐opioid receptor (MOR) have examined those located at cell bodies. However,... The majority of studies examining desensitization of the μ-opioid receptor (MOR) have examined those located at cell bodies. However, MORs are extensively... Background and Purpose The majority of studies examining desensitization of the μ‐opioid receptor ( MOR ) have examined those located at cell bodies. However,... Background and Purpose The majority of studies examining desensitization of the µ-opioid receptor (MOR) have examined those located at cell bodies. However,... BACKGROUND AND PURPOSEThe majority of studies examining desensitization of the μ-opioid receptor (MOR) have examined those located at cell bodies. However,... Background and Purpose The majority of studies examining desensitization of the mu -opioid receptor (MOR) have examined those located at cell bodies. However,... |
SourceID | pubmedcentral proquest crossref pubmed wiley |
SourceType | Open Access Repository Aggregation Database Index Database Publisher |
StartPage | 469 |
SubjectTerms | Action Potentials Analgesics, Opioid - pharmacology Animals desensitization Dopaminergic Neurons - drug effects Dopaminergic Neurons - physiology Enkephalin, Ala-MePhe-Gly- - pharmacology Enkephalin, Methionine - pharmacology GABAergic Neurons - drug effects GABAergic Neurons - physiology GPCR kinase (GRK) In Vitro Techniques Male Mice, Inbred C57BL morphine Morphine - pharmacology nerve terminal opiate opioid PKC Protein Kinase C - physiology Receptors, Opioid, mu - agonists Receptors, Opioid, mu - physiology Themed Section: Opioids: New Pathways to Functional Selectivity tolerance ventral tegmental area (VTA) Ventral Tegmental Area - physiology |
SummonAdditionalLinks | – databaseName: Wiley Online Library Open Access dbid: 24P link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3NbtQwEB6VcuGCyn_aggaEKg4N2mQd2xEnQKxWHNAeWqm3yHZm6UpVdkWWSr313gsPxDPwEDwJYztJu6pA3KLYkWKNx_ONPf4-gNeGo6Qe8eTlaEGp0M6mRpWUkrW2MMLktQtsn1_k9Fh8PilOtuBdfxcm8kMMG27eM8J67R3c2PaGk9vV6dvMo_E7cNczxvh6vlzMhiMEoVSUL_AsiJnWHa2QL-MZPt0MRrcQ5u1CyZsANkSgyQ7c76Ajvo-2fgBb1DyEg1nknr44xKPrq1TtIR7g7JqV-uIRXE04gsWNP2yD-E2QjUDT1OgF5n9f_ugFcR3hco6_fvKr5WqxXNTIyyKtODvH2l9W8mVe8fYmmjU2vmYSu6KasxYXDTKoRL-lQHgeh8TNX6OKABpGqY_hePLp6OM07ZQYUieULNiGVJfK6pEjI8noWplsNJ5L0jZXc-IcyrpSe54fKVVWOgZlrrZklVJOOT0eP4HtZtnQM0A2FWd4RvNUYDDEgEHYfDwvC005MZSkBF71JqlWkXCj6hMVtlsV7JbAfm-sqvO5tmJk6SVts0wm8HJoZm_xRyCmIR429xG8ZHHWOPpXn1KUUqs8T-BptP_wJwyGOMPKVAJqY2YMHTxb92ZLszgNrN1eF6yUWQJvwhz6--CqD7NpeNj9_657cI-RXBH3hvZhe_3tOz1ntLS2L4JX_AEcTxcm priority: 102 providerName: Wiley-Blackwell |
Title | Functional selectivity and time‐dependence of μ‐opioid receptor desensitization at nerve terminals in the mouse ventral tegmental area |
URI | https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fbph.12605 https://www.ncbi.nlm.nih.gov/pubmed/24467517 https://www.proquest.com/docview/1639508116 https://search.proquest.com/docview/1640482610 https://search.proquest.com/docview/1694968722 https://pubmed.ncbi.nlm.nih.gov/PMC4292961 |
Volume | 172 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NatwwEB6yOfUSmv6kTtMwLSH0EO-uvbYlH9vQ7VJo8CGBvRlJnm0Midd0N4U8QV-qz9Bn6kiyNwmhPfRiDBLYYkaab6TR9wEcKY6ScszOy9GCwkQaHSqRU0ha61QlKq6MY_s8y2YXyZd5Ot-CtL8L44r2ja6HzdX1sKkvXW1le21GfZ3YqPh6aiWW8iwaDWDADtqn6N3RQSKEly2w7IeRlB2dkC3f0e3lMLIA3lIAcx4kUqdTdi8ePQKZj2sl72NYF4SmT2GnQ4_4wf_lLmxR8wyOC08_fXuC53e3qVYneIzFHTH17XP4OeUg5vf-cOX0b5xyBKqmQqsxH_aKuIZwucDfv8JlWy_rCnlVpJaTc6zsXSVb5eUvb6JaY2NLJrGrqblaYd0gY0q0OwqEP_xwuPmbFxFAxSD1BVxMP52fzsJOiCE0ichSNiFVudBybEhlpGQlVDSeLDKSOhYL4hRKm1xamp8sE1FuGJOZSpMWQhhh5GTyErabZUOvABmAcoKnJHsCYyHGC4mOJ4s8lRQTI0kK4F1vjrL1fBtln6ew-UpnvgAOekOV3ZRblQwsraJtFGUBvN0082SxJyCqIR4290l4xeKkcfyvPnmSZ1LEcQB73vabP-mdJgDxwCs2HSxZ98MW9mFH2t35bADvnf_8fXDlx2LmXvb_-yOv4QnjutTvFB3A9vr7Db1h7LTWhzCIk4Kfn-fRoZs3fwAxqR5j |
link.rule.ids | 230,315,730,783,787,888,11575,27937,27938,46065,46489,53805,53807 |
linkProvider | National Library of Medicine |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3LbtQwFL0qZQEb3o9AgQtCFYsmk2SS2FlCxWiAtprFFHUX2Y6HRrSZiJkilR_gp_gGvolrO562VCDBLpItJU6Oc8-1r88BeCkoSvKYwEvRQocZVzIUrNShllLmIhNpraza514x3s_eH-QHa5D7szC2aF_JJmqPjqO2ObS1ld2xGvg6scFkd9tYLJVFMrgCV2m-xrlP0vvNg4wxZ1xg9A8TzntBIVPAI7vDKDEU3ogAUybEcutUdi4iXaKZl6slz7NYG4ZGN-GjH4CrPvkcnSxlpL79pu34zyO8BTd6YoqvXfNtWNPtHdicOGXr0y2cnh3UWmzhJk7ONK9P78L3EcVHt6yIC2utY00pULQ1Gvv60JvtKo3zGf78Ec67Zt7USD9c3VHej7U5BmUKyNy5UBRLbE01JvblOkcLbFokuopmsULjV_eeqPmT8ydAQfz3HuyP3k63x2Hv8RCqjBU5oUPXJZM8VloUWvCaiSQezgrNZcpmmrIzqUpuFISKgiWlIrqnaqklY0wxxYfD-7Dezlv9EJC4LeWOghPIiGYRFclkOpyVOdepJpKqA3jhv3PVOSmPyqdAhIvK4iKADY-Aqp_Ni4o4qzHLTZIigOerZpqHZnNFtJqGTX0y-hlSPhr_rU-ZlQVnaRrAAweq1ZN4NAbALsBt1cHogF9sIfBYPfAeLAG8ssD88-CqN5OxvXj03zd5BtfG092daufd3ofHcJ3oY-4WpDZgffnlRD8hiraUT-2E_AW3VT6T |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3LbtQwFL2CIiE25U0DLVwQqlg0mUkmiZ1lKYyGV5VFK1VsIttxaNQ2E3WmSOUH-Cm-gW_i2k6mUypYdBfJlhInx7nn2tfnALwWFCX5kMBL0UL7MVfSFyzTvpZSJiIWUams2uduOtmPPx4kB0tWX7ZoX8k6aI5PgqY-tLWV7Yka9HVig_zLjrFYytJw0JbV4CbcSoxoep-odxsIMWPOvMBoIIacd6JCpohHtodBaGi8EQKmbIgl1q1sKSpdoZpXKyaXmawNReO78LUfhKtAOQrO5jJQP_7Sd7zWKO_BakdQcdt1uQ83dPMANnOncH2-hXsXB7ZmW7iJ-YX29flD-DmmOOmWF3FmLXasOQWKpkRjY-_3prtK47TC37_8aVtP6xLpx6tbyv-xNMehTCGZOx-KYo6NqcrErmzneIZ1g0Rb0SxaaPzu3hU1f3M-BSiIBz-C_fH7vZ2J33k9-CpmaUIo0WXGJB8qLVIteMlEOBxVqeYyYpWmLE2qjBsloTRlYaaI9qlSaskYU0zx0egxrDTTRq8BEselHFJwAhvRLaIksYxGVZZwHWkiq9qDV_23Llon6VH0qRBho7DY8GC9R0HRzepZQdzVmOaGYerBy0UzzUezySIaTcOmPjH9FCkvHf6vTxZnKWdR5METB6zFk_SI9IBdgtyig9EDv9xCALK64B1gPHhjwfnvwRVv84m9eHrtm7yA2_m7cfH5w-6nZ3CHWGTi1qXWYWV-eqY3iKnN5XM7J_8Ahd9BEw |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Functional+selectivity+and+time-dependence+of+%CE%BC-opioid+receptor+desensitization+at+nerve+terminals+in+the+mouse+ventral+tegmental+area&rft.jtitle=British+journal+of+pharmacology&rft.au=Lowe%2C+J+D&rft.au=Bailey%2C+C+P&rft.date=2015-01-01&rft.eissn=1476-5381&rft.volume=172&rft.issue=2&rft.spage=469&rft.epage=481&rft_id=info:doi/10.1111%2Fbph.12605&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0007-1188&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0007-1188&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0007-1188&client=summon |